These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 15082085)

  • 41. Effects of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide, and somatostatin on the release of thyrotropin from the bullfrog pituitary.
    Okada R; Yamamoto K; Ito Y; Chartrel N; Leprince J; Fournier A; Vaudry H; Kikuyama S
    Ann N Y Acad Sci; 2006 Jul; 1070():474-80. PubMed ID: 16888212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The neuropeptide pituitary adenylate cyclase activating polypeptide modulates Ca2+ and pro-inflammatory functions in human monocytes through the G protein-coupled receptors VPAC-1 and formyl peptide receptor-like 1.
    El Zein N; Badran B; Sariban E
    Cell Calcium; 2008 Mar; 43(3):270-84. PubMed ID: 17651798
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Newly-identified receptors for peptide histidine-isoleucine and GHRH-like peptide in zebrafish help to elucidate the mammalian secretin superfamily.
    Wu S; Roch GJ; Cervini LA; Rivier JE; Sherwood NM
    J Mol Endocrinol; 2008 Nov; 41(5):343-66. PubMed ID: 18757498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Duplicated receptors for VIP and PACAP (VPAC1R and PAC1R) in a teleost fish, Fugu rubripes.
    Cardoso JC; Power DM; Elgar G; Clark MS
    J Mol Endocrinol; 2004 Oct; 33(2):411-28. PubMed ID: 15525598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pituitary adenylate cyclase-activating polypeptide directly modulates the activity of proopiomelanocortin neurons in the rat arcuate nucleus.
    Mounien L; Bizet P; Boutelet I; Gourcerol G; Fournier A; Vaudry H; Jégou S
    Neuroscience; 2006 Nov; 143(1):155-63. PubMed ID: 16962718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles.
    Ashok B; Rubinstein I; Tsueshita T; Onyüksel H
    Peptides; 2004 Aug; 25(8):1253-8. PubMed ID: 15350692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does autoimmunity of endogenous vasoactive neuropeptides cause retinopathy in humans?
    Staines DR
    Med Hypotheses; 2008; 70(1):137-40. PubMed ID: 17560049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?
    Staines DR; Brenu EW; Marshall-Gradisnik S
    Neuropsychiatr Dis Treat; 2009; 5():81-9. PubMed ID: 19557103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of AMPA receptor-mediated ion current by pituitary adenylate cyclase-activating polypeptide (PACAP) in CA1 pyramidal neurons from rat hippocampus.
    Costa L; Santangelo F; Li Volsi G; Ciranna L
    Hippocampus; 2009 Jan; 19(1):99-109. PubMed ID: 18727050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PACAP-related peptide (PRP)--molecular evolution and potential functions.
    Tam JK; Lee LT; Chow BK
    Peptides; 2007 Sep; 28(9):1920-9. PubMed ID: 17714829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of feeding behavior by pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) in vertebrates.
    Matsuda K; Maruyama K
    Peptides; 2007 Sep; 28(9):1761-6. PubMed ID: 17466413
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants.
    Shoenfeld Y; Agmon-Levin N
    J Autoimmun; 2011 Feb; 36(1):4-8. PubMed ID: 20708902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of vasoactive intestinal peptide in inflammation and autoimmunity.
    Gonzalez-Rey E; Delgado M
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neurotransmitters co-existing with VIP or PACAP.
    Fahrenkrug J; Hannibal J
    Peptides; 2004 Mar; 25(3):393-401. PubMed ID: 15134862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PACAP deficient mice display reduced carbohydrate intake and PACAP activates NPY-containing neurons in the rat hypothalamic arcuate nucleus.
    Nakata M; Kohno D; Shintani N; Nemoto Y; Hashimoto H; Baba A; Yada T
    Neurosci Lett; 2004 Nov; 370(2-3):252-6. PubMed ID: 15488333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of PACAP and related peptides on leptin, soluble leptin receptor and resistin in normal condition and LPS-induced inflammation.
    Yu R; Xie S; Chen J; Zhang L; Dai Y
    Peptides; 2009 Aug; 30(8):1456-9. PubMed ID: 19465076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Central administration of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide differentially regulates energy metabolism in chicks.
    Tachibana T; Oikawa D; Adachi N; Boswell T; Furuse M
    Comp Biochem Physiol A Mol Integr Physiol; 2007 May; 147(1):156-64. PubMed ID: 17291802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Guillain-Barré syndrome: a true case of molecular mimicry.
    Ang CW; Jacobs BC; Laman JD
    Trends Immunol; 2004 Feb; 25(2):61-6. PubMed ID: 15102364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of pituitary adenylate cyclase-activating polypeptide 38 (PACAP38) on tissue oxygen content--treatment in central nervous system of mice.
    Ohtaki H; Dohi K; Yofu S; Nakamachi T; Kudo Y; Endo S; Aruga T; Goto N; Watanabe J; Kikuyama S; Shioda S
    Regul Pept; 2004 Dec; 123(1-3):61-7. PubMed ID: 15518894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Infections and autoimmune diseases.
    Bach JF
    J Autoimmun; 2005; 25 Suppl():74-80. PubMed ID: 16278064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.